TABLE 4.
The rheumatic disease and treatment at baseline for participants in the ADIRA (Anti-inflammatory Diet in Rheumatoid Arthritis) trial who completed ≥1 diet period: anti-inflammatory diet (intervention) and/or a diet nutritionally similar to a typical Swedish diet (control)1
| Mean ± SD or n (%) | Median [IQR] | |
|---|---|---|
| Disease duration, y | 20.0 ± 9.5 | 19.2 [10.6–28.2] |
| DAS28-ESR | 3.8 ± 0.9 | 3.7 [3.0–4.6] |
| DAS28-CRP | 3.6 ± 0.8 | 3.5 [2.9–4.1] |
| Tender joint count (0–28) | 4.1 ± 4.2 | 2.0 [1.0–6.0] |
| Swollen joint count (0–28) | 1.8 ± 1.6 | 1.0 [1.0–2.0] |
| ESR, mm | 19.2 ± 10.8 | 20.0 [11.0–26.0] |
| CRP, mg/L | 4.2 ± 4.7 | 3.0 [1.0–6.0] |
| VAS-GH, mm | 44 ± 22 | 43 [26–59] |
| ACPA and/or RF positive | 34 (72) | |
| Drug treatment | ||
| Non-NSAID analgesic | 13 (28) | |
| NSAIDs | 24 (51) | |
| DMARDs | 42 (89) | |
| DMARD anti-TNF | 16 (34) | |
| DMARD methotrexate | 31 (66) | |
| DMARD sulfalazin | 6 (13) | |
| Blood pressure lowering | 20 (43) | |
| Glucocorticoids | 12 (26) | |
1
n = 47. ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS28, Disease Activity Score-28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, nonsteroidal anti-inflammatory drug; RF, rheumatoid factor; VAS-GH, visual analog scale for general health.